4.3 Article

Effect of single-incision plus one port laparoscopic surgery assisted with enhanced recovery after surgery on colorectal cancer: study protocol for a single-arm trial

Journal

TRANSLATIONAL CANCER RESEARCH
Volume 10, Issue 12, Pages 5443-5453

Publisher

AME PUBL CO
DOI: 10.21037/tcr-21-1361

Keywords

Colorectal cancer; laparoscopic surgery; single-incision plus one port laparoscopic surgery (SILS plus one); enhanced recovery after surgery (ERAS); study protocol

Categories

Funding

  1. Natural Science Foundation of Guangdong Province of China [2018A030313537]

Ask authors/readers for more resources

This study aims to evaluate the safety and feasibility of SILS plus one with ERAS protocol in colorectal cancer patients, focusing on postoperative hospital stay as the primary endpoint. Secondary endpoints include rehabilitative rate, medical cost, pain score, recovery indexes, inflammatory immune response, compliance with ERAS measures, 6MWT, hospital readmissions, and early postoperative complications.
Background: Studies have proved that the enhanced recovery after surgery (ERAS) protocol can significantly improve the recovery course of patients during the perioperative period. The application of minimally invasive surgery is a critical component of ERAS protocol. Single-incision plus one port laparoscopic surgery (SILS plus one) could achieve further minimally invasive surgical results than conventional laparoscopic surgery (CLS). The objective of this trial is to evaluate the safety and feasibility of SILS plus one with ERAS protocol in colorectal cancer. Methods: This is a prospective, single-center, open-label, single-arm trial. A total of 120 eligible patients with colorectal cancer will receive SILS plus one followed by the ERAS management during the perioperative period. The primary endpoint is postoperative hospital stay. The secondary endpoints include rehabilitative rate of the fourth postoperative day, postoperative medical cost, postoperative pain score, postoperative recovery indexes, inflammatory immune response indexes, compliance with ERAS measures, 6 min postoperative walking test (6MWT), hospital readmissions, and early postoperative complications. Discussion: This trial will be the first to evaluate the short-term outcomes of SILS plus one assisted with ERAS protocol for patients with colorectal cancer and will provide valuable clinical evidence on the benefit of the combination of these two techniques, hopefully, to provide patients with more safe, economic, feasible, and rapid surgery and perioperative strategies. Trial Registration: Clinical Trial Registry, NCT0426829. Registered February 15, 2020 (https:// clinicaltrials.gov/ct2/show/NCT04268290).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available